Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.47 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 8/20 | 0.44 |
| ▸ | ERAP1 | Q9NZ08 | 5/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4199245 | 0.93 | HTR6 (0.49) | HTR6QRFPRMCL1ERAP1ERAP2 | |
| SCHEMBL4209482 | 0.90 | HTR6 (0.46) | HTR6QRFPRERAP1ERAP2ALPL | |
| SCHEMBL4202567 | 0.89 | HTR6 (0.57) | HTR6QRFPRMCL1LMNAALDH1A1 | |
| SCHEMBL4202446 | 0.88 | HTR6 (0.44) | HTR6QRFPRMCL1ERAP1ERAP2 | |
| SCHEMBL4199399 | 0.86 | HTR6 (0.49) | HTR6QRFPRLMNAALDH1A1 | |
| SCHEMBL4202335 | 0.86 | HTR6 (0.47) | HTR6QRFPRLMNAALDH1A1 | |
| SCHEMBL4211828 | 0.85 | KMT2A (0.45) | HTR6QRFPRLMNA | |
| SCHEMBL4204701 | 0.85 | PSEN1 (0.48) | HTR6QRFPRERAP1ERAP2MOGAT2 | |
| SCHEMBL4198408 | 0.85 | HTR6 (0.49) | HTR6QRFPRALDH1A1 | |
| SCHEMBL4207391 | 0.85 | HTR6 (0.49) | HTR6QRFPRALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030038-A1 | Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | claimed |
| US-20090030038-A1 | Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030038-A1 | Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor | HTR6, HTR1A, HTR1D | HTR6 1/4885QRFPR 81/4885MCL1 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.